Recombinant IL-1 RA in human Chronic lymphocytic leukemia cells in vitro
Inflammatory factors that activate NFkB play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL) but are not addressed specifically by current therapies. Interleukin-1 (IL-1) is a master-regulator of inflammation that is inhibited safely in humans by the IL-1 receptor antagonist anakinra. Anakinra (K) was found to inhibit NFkB activity in CLL cells in an IL-1 receptor independent manner and had properties of an intracellular anti-oxidant in vitro. Overall design: Purified human CLL B cells were cultured with or without 300 microg/ml of anakinra for 48h before RNA was extracted and total RNA sequencing performed.